Does metabolomic subtyping identify distinctive cardiovascular risk profiles in patients with NAFLD?
Metabolomic subtyping in NAFLD patients identifies distinct subgroups with varying cardiovascular risk profiles, potentially improving clinical risk stratification.
Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.
Martínez‐Arranz et al. (Sun,) studied this question.